Tumor microenvironment-responsive spherical nucleic acid nanoparticles for enhanced chemo-immunotherapy.

Abstract in brief

• The study develops a new, self-assembling nanoparticle system (MCMD NPs) that combines chemotherapy and immunotherapy, using spherical nucleic acids with adjuvants and the drug doxorubicin to target tumors more effectively.
• These nanoparticles are designed to release doxorubicin in response to tumor-specific enzymes (MMP9), increasing drug accumulation and killing tumor cells more efficiently, while also boosting the immune response against cancer.
• The overall approach avoids some common challenges in nanocarrier systems, like low drug loading and toxicity, offering a promising new method for enhancing cancer treatment through combined chemoimmunotherapy.